EC Number   |
Application |
Reference |
|---|
    5.1.3.2 | medicine |
drug design |
672430 |
| 5.1.3.2 | medicine |
Galactosylation of one or more glycoprotein(s), most likely in the endosomal/lysosomal system, is essential for the survival of bloodstream form Trypanosoma brucei. GalE-encoded epimerase and the downstream UDP-Gal transporters and UDP-Gal-dependent glycosyltransferases may be exploitable as drug targets. |
673409 |
| 5.1.3.2 | medicine |
SjGALE is a potential vaccine against Schistosoma japonicum |
728581 |
| 5.1.3.2 | medicine |
The absence of CaGAL10 alone does not significantly reduce virulence in mouse model studies, but since it leads to increased drug sensitivity, it can be explored as a potential drug target in combination with other candidacidal drugs. Thus the UDP-galactose-4-epimerase plays an important role in the biology of the human pathogen, Candida albicans, like in the case of several other pathogens. |
673819 |
| 5.1.3.2 | medicine |
Trypanosoma brucei GalE is a validated drug target for African sleeping sickness. The Trypanosoma brucei enzyme can be selectively inhibited by small molecules that are not substrate analogues in vitro, although the mechanism of cytotoxicity of these inhibitors is unconfirmed. Of the compounds screened, ethacrynic acid displays the best therapeutic index, but is clinically used as a loop diuretic and was found to form multiple covalent adducts with TbGalE in vitro, limiting its potential as a lead compound. |
672608 |
| 5.1.3.2 | synthesis |
preparation of a fusion enzyme consisting of UDP-galactose 4-epimerase and galactose-1-phosphate uridylyltransferase with an intervening Ala3 linker, shows kinetic advantages in that the initial velocity to produce glucose 1-phosphate from UDPgalactose an |
2335 |
